TickerFacts.

Allogene Therapeutics, Inc. (ALLO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$196.96M
Year ended 2025-12-31
-$168.65M
Trailing 12 months to 2026-06-30
2018-12-31: -$191.84M2019-12-31: -$197.41M2020-12-31: -$250.84M2021-12-31: -$169.69M2022-12-31: -$321.24M2023-12-31: -$313.54M2024-12-31: -$259.56M2025-12-31: -$196.96M-$196.96M
2018-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$196.96Mn/m2026-03-12, From 2025-01-01
2024-12-31-$259.56Mn/m2026-03-12, From 2024-01-01
2023-12-31-$313.54Mn/m2025-03-13, From 2023-01-01
2022-12-31-$321.24Mn/m2024-03-14, From 2022-01-01
2021-12-31-$169.69Mn/m2024-03-14, From 2021-01-01
2020-12-31-$250.84Mn/m2024-03-14, From 2020-01-01
2019-12-31-$197.41Mn/m2022-02-23, From 2019-01-01
2018-12-31-$191.84Mn/a2021-02-25, From 2018-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Allogene Therapeutics, Inc. (ALLO)2025-12-31-$196.96Mn/m
Vaxart, Inc. (VXRT)2025-12-31$26.65Mn/m
Amgen Inc (AMGN)2025-12-31$14.25B+10.9%
Repligen Corp (RGEN)2025-12-31$133.91M+287.5%
Champions Oncology, Inc. (CSBR)2026-04-30$237.0K-96.2%
Bio-Techne Corp (TECH)2026-06-30$349.25M+64.6%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$35.92Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$342.38Mn/m
Vericel Corp (VCEL)2025-12-31$22.59M+125.4%

Compare ALLO, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗